Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 19Recruiting 12Unknown 9Terminated 4Enrolling by invitation 3Withdrawn 2Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 40Breast Neoplasms 38Prostatic Neoplasms 24Colorectal Neoplasms 23Uterine Cervical Neoplasms 16Carcinoma, Non-Small-Cell Lung 13Anxiety Disorders 13Stomach Neoplasms 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Lung Neoplasms 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Esophageal Neoplasms 7Sarcoma 6Ovarian Neoplasms 6Esophageal Squamous Cell Carcinoma 6Depression 6Colonic Neoplasms 6Uterine Cervical Dysplasia 5Small Cell Lung Carcinoma 5Pain 5Glioma 5Epilepsy 5Dementia 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Enrolling by invitation × Interventional × Adenoviridae Infections × Clear all
NCT06763965 2026-03-23

Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1/2 Enrolling by invitation
30 enrolled
CNS

Adenoviridae Infections, Glioma

NCT06215846 2025-11-26

A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors

Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Phase 1 Enrolling by invitation
12 enrolled

Adenoviridae Infections

NCT06027879 2025-06-25

Gamma Capture

University of Pittsburgh

Phase 1/2 Enrolling by invitation
25 enrolled

Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡